PMCB

AcronymDefinition
PMCBPlant Molecular and Cellular Biology (graduate program; University of Florida)
PMCBProbabilistic Modelling in Computational Biology
PMCBParticulate Marrow Cancellous Bone
PMCBPartial Mission Capable Both
PMCBPreventive Maintenance Checks and Balances
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
There are various schemes that fully depend on anchor nodes such as MCL, dual and mixture MCL, MCB, and PMCB, and there are others that combine anchor and normal nodes location information like [MSL.sup.*], WMCL, RMCL, COMCL, IMCL, and Orbit.
The MCL, dual and mixture MCL, and PMCB schemes draw a circle over the previous sample to observe whether it satisfies the anchor nodes constraints in the current time.
- US-based biotechnology company PharmaCyte Biotech, Inc.'s (OTCQB: PMCB) PCT patent application covering a targeted therapy to treat solid cancerous tumors was published on 27 September (Publication No.
- US-based clinical stage biotechnology company PharmaCyte Biotech, Inc.'s (OTCQB: PMCB) partner, Austrianova, has successfully performed an additional pre-production "engineering run" using the Cell-in-a-Box encapsulated cells that will be used, in combination with low doses of the cancer prodrug ifosfamide, for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer, the company said.
(OTCQB: PMCB) has successfully completed a study on the stability after "hand thawing" syringes of the Cell-in-a-Box encapsulated cells that will be used, in combination with low doses of the cancer prodrug ifosfamide, for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC), the company said.
(OTCQB: PMCB) will encapsulate and then use in its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer have successfully passed all 29 tests required by the US Food and Drug Administration, the company said.
- Vials of cells from Laguna Hills, California-based cellular therapies developer PharmaCyte Biotech, Inc.'s (OTCQB: PMCB) master cell bank (MCB) have been shipped by Eurofins Lancaster Laboratories to Austrianova's encapsulation facility in Thailand, the company said.
(OTCQB: PMCB) has filed a patent application with the US Patent and Trademark Office (USPTO) to protect its therapy to treat cancerous tumors, including the therapy that will be used in its upcoming clinical trial in locally advanced, non-metastatic, inoperable pancreatic cancer, the company said.
- Laguna Hills, California-based cellular therapies developer PharmaCyte Biotech, Inc.'s (OTCQB: PMCB) 6-month study on storage of the frozen encapsulated cells necessary for the determination of an "initial shelf life" has been successfully completed by Austrianova, the company said.
- Production of the cells necessary to prepare US-based biotechnology company PharmaCyte Biotech, Inc.'s (OTCQB: PMCB) Master Cell Bank has started, the company said.
(OTCQB: PMCB) selected to prepare its master cell bank (MCB), Eurofins Lancaster Laboratories, has successfully completed its independent growth evaluation of the cells that PharmaCyte will use in its Cell-in-a-Box-based pancreatic cancer therapy, the company said.